Clinical trials for Lung cancer

300 currently recruiting clinical trials

Phase 2 Lung cancer #NCT05967689 #2023-503865-48-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Taiho Oncology
Phase 2 Lung cancer #NCT06712316 #2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies
20 recruiting sites
BioNTech SE
Phase 2 Lung cancer #NCT07001618
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Lung cancer #NCT06627738
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
EGFR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Centre Antoine Lacassagne
Phase 2 Lung cancer #NCT06448754 #2023-509482-20-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
EGFR
5 recruiting sites
AstraZeneca
Phase 2 Lung cancer #NCT06552234
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
None 1 2 3 or more
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy Targeted therapy
20 recruiting sites
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Phase 2 Lung cancer #NCT04127110
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Targeted therapy
4 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Lung cancer #NCT05061550 #2023-508852-21-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
6 recruiting sites
AstraZeneca
Phase 2 Lung cancer #NCT04614103
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
Excluded genetic anomalies
ALK EGFR ROS-1
6 recruiting sites
Iovance Biotherapeutics